Miniaturized Pancreatic Cancer Organoids Retain Drug-Sensitivity Rankings
Microencapsulated cultures used 0.5 μL instead of 50 μL while producing similar sensitivity rankings across five standard chemotherapy drugs.
Method Profile
Pancreatic Organoid Drug-Ranking Comparison After Microencapsulation
Compare whether smaller pancreatic tumor organoid cultures preserve drug-sensitivity stratification.
Research Applications
Evaluate assay miniaturization for material-limited pharmacological screening.
Model & Design
Patient-derived pancreatic cancer organoids in 0.5 μL microencapsulated and 50 μL conventional cultures.
Experimental Format
The same five standard-of-care chemotherapy drugs are compared between culture formats.
Model Components
- Component
Models and formats
- Description
Patient-derived pancreatic cancer organoids in droplet-microfluidic microencapsulation and conventional culture.
- Component
Drug comparison
- Description
Five standard-of-care chemotherapy compounds evaluated in both formats.
Measurements & Endpoints
- Relative drug-sensitivity ranking
- Agreement of sensitivity stratification
Analysis
Compare the relative drug-sensitivity ranking across paired microencapsulated and conventional cultures.
Published Evidence
- Study Design
Paired drug-response comparison after a 100-fold culture-volume reduction.
- Study Sample
Patient-derived pancreatic cancer organoids in paired culture formats, tested with five standard-of-care chemotherapy drugs.
- Comparison
0.5 μL microencapsulated versus 50 μL conventional organoid cultures.
- Finding
Drug-sensitivity stratification was nearly identical across the two formats.
- Interpretation & Limits
- The reported result concerns relative drug-response ordering.